Yijing Capital
Yijing Capital is an investment company established in 2015 and headquartered in Shanghai, China, with regional offices in Beijing, Hong Kong, Singapore, and Sydney. As a sister company of Yizhou Group, which ranks among China's Top 500 companies, Yijing Capital leverages decades of experience across various industries. The firm primarily focuses on the medical and health-care sector, as well as smart manufacturing, and aims to identify opportunities in high-growth industries. Yijing Capital operates multiple investment platforms and engages in equity investments using both proprietary and externally sourced funds. The company's core team possesses extensive operational and managerial expertise, enabling them to undertake a diverse range of investment projects both domestically and internationally, including sectors such as artificial intelligence, new retail, education, and new energy. Yijing Capital has successfully completed numerous investments, with several portfolio companies achieving significant growth and some going public, while also realizing substantial returns from strategic exits.
Xgene Pharmaceutical
Series C in 2021
Xgene Pharmaceutical Inc. is a late-clinical stage pharmaceutical company established in 2015, based in the Cayman Islands. It focuses on developing small-molecule drugs aimed at treating chronic pain, infectious diseases, and tumors. Utilizing proprietary linker technology, Xgene creates novel, multimodal conjugated molecules that enhance the efficacy and tolerability of pain medications. The company's current programs are dedicated to addressing unmet needs in neurological disorders, making significant strides in the development of innovative treatments for these conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.